Evidence map›Paper›PMID 42132422›Full record

ArticleJournal of virology2026

Genotypic and phenotypic characteristics of CXCR4-using transmitted/founder HIV-1 envelope glycoproteins.

Dorine Martres, Théo Montagné, Sandra Pani, Nicolas Jeanne, Marie Armani-Tourret, Mary Requena, Camille Vellas, Stéphanie Raymond, Valérie Lorin, Yohan Gallois and 5 more

Abstract read
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Dorine MartresInfinity - Toulouse Institute for Infectious and Inflammatory Diseases, INSERM UMR 1291, CNRS UMR 5051, University of Toulouse, Toulouse, France.ORCID 0009-0009-0375-3060
Théo MontagnéInfinity - Toulouse Institute for Infectious and Inflammatory Diseases, INSERM UMR 1291, CNRS UMR 5051, University of Toulouse, Toulouse, France.
Sandra PaniInfinity - Toulouse Institute for Infectious and Inflammatory Diseases, INSERM UMR 1291, CNRS UMR 5051, University of Toulouse, Toulouse, France.
Nicolas JeanneInfinity - Toulouse Institute for Infectious and Inflammatory Diseases, INSERM UMR 1291, CNRS UMR 5051, University of Toulouse, Toulouse, France.ORCID 0000-0001-7109-3353
Marie Armani-TourretInfinity - Toulouse Institute for Infectious and Inflammatory Diseases, INSERM UMR 1291, CNRS UMR 5051, University of Toulouse, Toulouse, France.
Mary RequenaInfinity - Toulouse Institute for Infectious and Inflammatory Diseases, INSERM UMR 1291, CNRS UMR 5051, University of Toulouse, Toulouse, France.
Camille VellasInfinity - Toulouse Institute for Infectious and Inflammatory Diseases, INSERM UMR 1291, CNRS UMR 5051, University of Toulouse, Toulouse, France.ORCID 0000-0002-8637-6695
Stéphanie RaymondInfinity - Toulouse Institute for Infectious and Inflammatory Diseases, INSERM UMR 1291, CNRS UMR 5051, University of Toulouse, Toulouse, France.ORCID 0000-0002-3780-5844
Valérie LorinInstitut Pasteur, Université Paris Cité, Humoral Immunology Unit, Paris, France.
Yohan GalloisService d'ORL, Otoneurologie et ORL Pédiatrique, CHU de Toulouse, Toulouse, France.
Bénédicte Puissant-LubranoInfinity - Toulouse Institute for Infectious and Inflammatory Diseases, INSERM UMR 1291, CNRS UMR 5051, University of Toulouse, Toulouse, France.ORCID 0000-0003-3457-833X
Hugo MouquetInstitut Pasteur, Université Paris Cité, Humoral Immunology Unit, Paris, France.
Pierre DelobelInfinity - Toulouse Institute for Infectious and Inflammatory Diseases, INSERM UMR 1291, CNRS UMR 5051, University of Toulouse, Toulouse, France.ORCID 0000-0002-2874-3581
Jacques IzopetInfinity - Toulouse Institute for Infectious and Inflammatory Diseases, INSERM UMR 1291, CNRS UMR 5051, University of Toulouse, Toulouse, France.ORCID 0000-0002-8462-3234
Bernard LaganeInfinity - Toulouse Institute for Infectious and Inflammatory Diseases, INSERM UMR 1291, CNRS UMR 5051, University of Toulouse, Toulouse, France.ORCID 0000-0002-3459-7867

Funding

Agence Nationale de Recherches sur le Sida et les Hépatites Virales ECTZ190224Sidaction
6 · The paper itself

Abstract

The characteristics of HIV-1 envelope glycoproteins (Env) that initiate infection remain incompletely understood. In the primary HIV infection (PHI) stage, Envs using CCR5 as entry coreceptor (R5-tropic Envs) are much more frequent than those using CXCR4, alone or in addition to CCR5 (X4 or R5X4 Envs). However, a comprehensive analysis of the genetic identity and functional properties of CXCR4-using Envs during PHI is lacking to attest whether they are less transmissible than R5 Envs. Here, Env populations in the plasma of 22 recently infected individuals with R5 or CXCR4-using viruses were characterized by single-genome amplification. Mathematical modeling of HIV evolution, phylogenetic analyses, and viral quasi-species complexity indices showed that infection with CXCR4-using viruses is most often initiated by one, occasionally two variants, similar to R5 viruses. After transmission, the diversity and complexity of CXCR4-using and R5 Env populations increase similarly during PHI, with mutations accumulating in preferential regions of the gp120 portion of Env, but not in gp41. Both Env types also shared similar traits influencing viral transmission (variable loop length, N-glycosylations) and T-cell- but non-macrophage-tropism. However, CXCR4-using Envs exhibited specific sensitivity profiles to neutralization by soluble CD4 and broadly neutralizing antibodies (bNAbs), suggesting differences in epitope exposure and conformational dynamics compared to R5 Envs. These results, therefore, indicate that CXCR4-using viruses are equipped to initiate infection and, like R5 viruses, undergo a genetic bottleneck during transmission. The specific antigenicity of transmitted CXCR4-using Envs could help improve protocols using bNAbs for passive immunization and HIV vaccine development. IMPORTANCE: Transmitted/founder (T/F) viruses are predominantly R5-tropic, and only on rare occasions have T/F viruses that use CXCR4 been reported in the literature. Consistently, R5 viruses account for over 90% of the viruses present during primary HIV infection (PHI). However, it remains unclear whether CXCR4-using Envs, unlike R5 Envs, lack key properties for virus transmission and/or persistence in the new host. Here, we found that transmitted CXCR4-using Envs shared with R5 Envs common genetic and functional determinants, demonstrating their potential to transmit infection. So, the low prevalence of CXCR4-using viruses among donors probably explains why they are infrequently transmitted. As with R5 viruses, a genetic bottleneck occurs during transmission of CXCR4-using viruses, suggesting that the barriers determining this bottleneck are independent of viral tropism. Remarkably, transmitted CXCR4-using Envs exhibit distinct antigenic properties compared to R5 Envs, which could be leveraged to improve broadly neutralizing antibody-based preventive and therapeutic vaccine strategies.

Indexed as

env Gene Products, Human Immunodeficiency VirusHIV-1HIV InfectionsReceptors, CXCR4Antibodies, NeutralizingGenotypeHIV AntibodiesHIV Envelope Protein gp120HIV Envelope Protein gp41HumansPhenotypePhylogenyReceptors, CCR5Antibodies, NeutralizingCXCR4 protein, humanenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesHIV Envelope Protein gp120HIV Envelope Protein gp41Receptors, CCR5Receptors, CXCR4broadly neutralizing antibodiesCXCR4envelope glycoproteinHIV transmissionprimary HIV infectionviral tropism

Identifiers

PMID42132422
PMCPMC13288616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.